SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Apricus Biosciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: OldBoar who wrote (1776)3/28/2016 12:02:30 PM
From: mokelumne river  Read Replies (2) of 2026
 
I have no idea what Denner is doing, other than he has made the same mistakes many of us made in his investments. Maybe he has mitigated his risks with shorting the stock.

What is clear is we are back to the reason I first invested, and that is Vitaros. We can only hope that the Sandoz thing, with what I understand was poor quality in a batch, is resolved quickly and that sales continue to increase in Europe. The other not so small issue is whether the FDA provides an easy (no more clinical trials) pathway to approval. With Pfizer now having a major stake through its acquisition of Allergan, perhaps there will not be a behind-the-scenes lobby against approval.

Of course, we now will have the possibility of delisting and a reverse split to avoid the latter. Anyone is welcome to provide some optimism.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News